Detalhe da pesquisa
1.
Expert consensus on palivizumab use for respiratory syncytial virus in developed countries.
Paediatr Respir Rev
; 33: 35-44, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31060948
2.
Extrauterine growth restriction in very preterm infant: etiology, diagnosis, and 2-year follow-up.
Eur J Pediatr
; 179(9): 1469-1479, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32193657
3.
Accurately Assessing the Expected Impact of Universal First Respiratory Syncytial Virus (RSV) Season Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants.
J Infect Dis
; 227(11): 1333-1334, 2023 05 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36520978
4.
Interaction between healthcare professionals and parents is a key determinant of parental distress during childhood hospitalisation for respiratory syncytial virus infection (European RSV Outcomes Study [EROS]).
Acta Paediatr
; 107(5): 854-860, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29341239
5.
Exploring respiratory syncytial virus prophylaxis for children with all grades of bronchopulmonary dysplasia.
Acta Paediatr
; 110(1): 25-27, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32691906
6.
Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants.
J Med Econ
; 26(1): 630-643, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37067826
7.
A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age.
PLoS One
; 18(8): e0289828, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37561741
8.
Trends in survival among extremely-low-birth-weight infants (less than 1000 g) without significant bronchopulmonary dysplasia.
BMC Pediatr
; 12: 63, 2012 Jun 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-22682000
9.
Identifying the research, advocacy, policy and implementation needs for the prevention and management of respiratory syncytial virus lower respiratory tract infection in low- and middle-income countries.
Front Pediatr
; 10: 1033125, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36440349
10.
The effects of varying protein and energy intakes on the growth and body composition of very low birth weight infants.
Nutr J
; 10: 140, 2011 Dec 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-22206271
11.
The impact of clinical maternal chorioamnionitis on neurological and psychological sequelae in very-low-birth weight infants: a case-control study.
J Perinat Med
; 39(2): 203-8, 2011 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-21299358
12.
The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children.
J Allergy Clin Immunol
; 126(2): 256-62, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20624638
13.
Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries.
Expert Rev Anti Infect Ther
; 19(4): 419-441, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32972198
14.
Adoption in Canada of an international risk scoring tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infants.
Curr Med Res Opin
; 37(7): 1149-1153, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33813989
15.
Effect of maternal clinical chorioamnionitis on neonatal morbidity in very-low birthweight infants: a case-control study.
J Perinat Med
; 38(3): 269-73, 2010 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-20121532
16.
Validation of a model to predict hospitalization due to RSV of infants born at 33-35 weeks' gestation.
J Perinat Med
; 38(4): 411-7, 2010 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-20297901
17.
Health economics and RSV.
Paediatr Respir Rev
; 10 Suppl 1: 12-3, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19651392
18.
Guidelines on CMV congenital infection.
J Perinat Med
; 37(5): 433-45, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19673682
19.
Respiratory syncytial virus prophylaxis for children with chronic lung disease: have we got the criteria right?
Expert Rev Anti Infect Ther
; 17(4): 211-222, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30739513
20.
Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants.
Front Pediatr
; 12: 1343960, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38283631